中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

44 records (took 0.023 seconds)

    System for benzodiazepine detection
    3.
    发明专利
    System for benzodiazepine detection 未知

    公开(公告)号：AU668824B2

    公开(公告)日：1996-05-16

    申请号：AU6716694

    申请日：1994-05-04

    Applicant: BIO RAD LABORATORIES

    Inventor： BINDER STEVEN R ,  KING DAVID L

    IPC: G01N30/02 ,  G01N30/06 ,  G01N30/08 ,  G01N30/14 ,  G01N30/34 ,  G01N30/46 ,  G01N30/74 ,  G01N30/86 ,  G01N30/88 ,  G01N33/94 ,  G01N33/493

    Abstract: Biological samples are analyzed for benzodiazepines in a single isocratic analysis using a chromatographic column system containing an immobilized enzyme reactor which cleaves glucuronic acid-conjugated benzodiazepines, an anion exchange column, a hydrophobic cation exchange column and a reverse-phase analytical column. Preferred methods of performing the analysis further involve the use of a hydrophobic cation exchange precolumn prior to the anion exchange column. The system readily lends itself to automation, automatic periodic sampling and benzodiazepine identification and quantification. The system is particularly well adapted to the determination and identification of benzodiazepines in urine samples.

    BORRELIA IMMUNOASSAYS AND MATERIALS THEREFOR
    4.
    发明申请
    BORRELIA IMMUNOASSAYS AND MATERIALS THEREFOR 审中-公开
    BORRELIA免疫测定仪及其材料

    公开(公告)号：WO2017062535A3

    公开(公告)日：2017-05-26

    申请号：PCT/US2016055618

    申请日：2016-10-06

    Applicant: BIO-RAD LABORATORIES INC

    Inventor： DELANOY MICHELLE ,  FLANAGAN JOHN ,  ARJOMANDI AUDREY ,  KAUL RAVI ,  BINDER STEVEN R

    IPC: C07K14/20 ,  C07K19/00 ,  G01N33/53 ,  G01N33/569

    CPC classification number: G01N33/56911 ,  C07K14/20 ,  G01N2333/20

    Abstract: The present invention relates to an immunoassay for the detection of Borrelia specific IgG, IgM and IgG/IgM antibodies in biological samples suspected of Lyme infection. The immunoassay can be performed via a standard immunoassay format or on an automated platform. In various embodiments, the immunoassay uses one or more Borrelia specific chimeric peptides VlsE-FlaB (designated pFlaB-mV), VlsE-ErpP (designated pErp59-mV), VlsE-P35 (designated pP35-mV) alone or in combination with one or more outer surface protein C (Osp C) types B or I, p58 and DbpA. Other aspects of the invention provide antigen/substrate combinations and compositions comprising combinations of the disclosed peptides and/or proteins for use in the immunoassays described herein.

    Abstract translation: 本发明涉及用于检测疑似莱姆病感染的生物样品中疏螺旋体属特异性IgG，IgM和IgG / IgM抗体的免疫测定法。 免疫测定可以通过标准的免疫测定方式或在自动化平台上进行。 在各种实施方案中，免疫测定法单独或与一种或多种疏螺旋体特异性嵌合肽VlsE-FlaB（命名为pFlaB-mV），VlsE-ErpP（命名为pErp59-mV），VlsE-P35（命名为pP35-mV） 更多外表面蛋白C（Osp C）B或I型，p58和DbpA。 本发明的其它方面提供了包含用于本文所述的免疫测定中的公开的肽和/或蛋白质的组合的抗原/底物组合和组合物。

    REDUCING NON-SPECIFIC BINDING IN IMMUNOASSAYS PERFORMED ON POLYMERIC SOLID PHASES
    5.
    发明申请
    REDUCING NON-SPECIFIC BINDING IN IMMUNOASSAYS PERFORMED ON POLYMERIC SOLID PHASES 审中-公开
    减少在聚合物固相上进行免疫测定中的非特异性结合

    公开(公告)号：WO03087342A2

    公开(公告)日：2003-10-23

    申请号：PCT/US0309919

    申请日：2003-03-28

    Applicant: BIO RAD LABORATORIES

    Inventor： WATKINS MICHAEL I ,  BINDER STEVEN R ,  RASKIN ALEKSANDER

    IPC: G01N33/543 ,  C12N

    CPC classification number: G01N33/54393 ,  Y10S435/962

    Abstract: Water-soluble polymer is added to the liquid phase in a heterogeneous immunoassay of serum, the polymer having monomers in common with monomers of the solid phase surface. This reduces non-specific binding of IgG's from the serum to the solid phase surface and thereby reduces the occurrence of false positive readings in the immunoassay.

    Abstract translation: 在血清的非均相免疫测定中将水溶性聚合物加入到液相中，该聚合物具有与固相表面的单体相同的单体。 这降低了IgG从血清到固相表面的非特异性结合，从而减少了免疫测定中假阳性读数的发生。

    PATTERN RECOGNITION METHOD FOR DIAGNOSIS OF SYSTEMIC AUTOIMMUNE DISEASES
    7.
    发明申请
    PATTERN RECOGNITION METHOD FOR DIAGNOSIS OF SYSTEMIC AUTOIMMUNE DISEASES 审中-公开
    用于诊断系统性自身免疫性疾病的模式识别方法

    公开(公告)号：WO2005103300A3

    公开(公告)日：2006-07-20

    申请号：PCT/US2005013637

    申请日：2005-04-20

    Applicant: BIO RAD LABORATORIES ,  BINDER STEVEN R ,  GLOSSENGER JOHN

    Inventor： BINDER STEVEN R ,  GLOSSENGER JOHN

    IPC: G01N33/48 ,  C12Q1/68 ,  G01N33/50 ,  G01N33/564 ,  G06F19/00 ,  G06F19/18 ,  G06F19/24

    CPC classification number: G01N33/564 ,  G01N2800/24 ,  G06F19/18 ,  G06F19/24 ,  G06K9/6276 ,  G16H50/20

    Abstract: An array of autoantibodies is quantitated in a patient sample and analyzed toward a diagnosis of systemic autoimmune diseases. The analysis uses any of various known pattern recognition techniques, for example k-nearest neighbor analysis, to compare the array of quantitation data to sets of data previously obtained from subjects having known systemic autoimmune diseases, thereby determining the particular disease(s) that the patient is suffering from as well as the degree of confidence or likelihood of accuracy of the determination. The method is effective in identifying a single disease and also in identifying two or more diseases simultaneously present. The method is readily susceptible to automated data processing, eliminating much of the human judgment and error that were previously entailed in diagnosing these diseases.

    Abstract translation: 在患者样品中量化一系列自身抗体，并对全身自身免疫性疾病的诊断进行分析。 该分析使用各种已知的模式识别技术中的任何一种，例如k-最近邻分析，将定量数据阵列与先前从具有已知的系统性自身免疫疾病的受试者获得的数据集合进行比较，从而确定特定的疾病 病人正在受苦，以及信心的程度或确定准确性的可能性。 该方法在鉴定单一疾病以及同时鉴定两种或更多种同时存在的疾病方面是有效的。 该方法容易受到自动数据处理的影响，消除了以前在诊断这些疾病方面的大部分人的判断和错误。

    PATTERN RECOGNITION METHOD FOR DIAGNOSIS OF SYSTEMIC AUTOIMMUNE DISEASES
    8.
    发明申请
    PATTERN RECOGNITION METHOD FOR DIAGNOSIS OF SYSTEMIC AUTOIMMUNE DISEASES 审中-公开
    用于诊断系统性自身免疫性疾病的模式识别方法

    公开(公告)号：WO0233415A3

    公开(公告)日：2003-03-27

    申请号：PCT/US0142213

    申请日：2001-09-19

    Applicant: BIO RAD LABORATORIES

    Inventor： BINDER STEVEN R ,  GLOSSENGER JOHN

    IPC: G01N33/564

    CPC classification number: G01N33/564

    Abstract: An array of autoantibodies is quantitated in a patient sample and analyzed toward a diagnosis of systemic autoimmune diseases. The analysis uses any of various known pattern recognition techniques to compare the array of quantitation data to sets of data previously obtained from subjects having known systemic autoimmune diseases, thereby determining the particular disease(s) that the patient is suffering from as well as the degree of confidence or likelihood of accuracy of the determination. The method is effective in identifying a single disease and also in identifying two or more diseases simultaneously present. The method is readily susceptible to automated data processing, eliminating much of the human judgment and error that were previously entailed in diagnosing these diseases.

    Abstract translation: 在患者样品中量化一系列自身抗体，并对全身自身免疫性疾病的诊断进行分析。 分析使用各种已知的模式识别技术中的任何一种将定量数据阵列与先前从具有已知的系统性自身免疫性疾病的受试者获得的数据集合进行比较，从而确定患者患有的特定疾病以及患者的程度 信心或准确性的确定的可能性。 该方法在鉴定单一疾病以及同时鉴定两种或更多种同时存在的疾病方面是有效的。 该方法容易受到自动数据处理的影响，消除了以前在诊断这些疾病方面的大部分人的判断和错误。

    FXIII DETECTION FOR VERIFYING SERUM SAMPLE AND SAMPLE SIZE AND FOR DETECTING DILUTION
    9.
    发明专利
    FXIII DETECTION FOR VERIFYING SERUM SAMPLE AND SAMPLE SIZE AND FOR DETECTING DILUTION 未知

    公开(公告)号：CA2447696C

    公开(公告)日：2011-01-18

    申请号：CA2447696

    申请日：2002-05-28

    Applicant: BIO RAD LABORATORIES

    Inventor： BINDER STEVEN R ,  GOODRICH JODI L ,  SAFARIAN ZARA

    IPC: G01N33/53 ,  G01N33/573 ,  G01N33/487 ,  G01N33/543 ,  G01N33/96

    Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.

    10.
    发明专利
    未知

    公开(公告)号：DE60229386D1

    公开(公告)日：2008-11-27

    申请号：DE60229386

    申请日：2002-05-28

    Applicant: BIO RAD LABORATORIES

    Inventor： BINDER STEVEN R ,  GOODRICH JODI L ,  SAFARIAN ZARA

    IPC: C07K16/36 ,  G01N33/53 ,  C07K16/00 ,  G01N33/96

    Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.

Patent Agency Ranking